Journals / JAREM / 2020 / Cilt: 10 - Sayı: 2

Is Mucopolysaccharidosis a Cause of Sleep and Speech Disorders? Report of Four Cases?

Mukopolisakaridozlar Uyku ve Konuşma Bozukluklarının Bir Nedeni midir?

Journal
JAREM
Pages
204–207
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, anddecreased HS sulphamidase activity, leading to the diagnosis of MPS III.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mucopolysaccharidosis type III (MPS 3) is an autosomal recessive disorder caused by a deficiency of one of the four enzymes involved in the lysosomaldegradation of heparan sulfate (HS).
📊
Key Findings & Data:It is often unrecognized or misdiagnosed in children as an idiopathic developmental/speech delay, attentiondeficit/hyperactivity disorder (ADHD), and/or autism spectrum disorder.
💡
Conclusion & Impact:Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, anddecreased HS sulphamidase activity, leading to the diagnosis of MPS III.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Mucopolysaccharidosis type III (MPS 3) is an autosomal recessive disorder caused by a deficiency of one of the four enzymes involved in the lysosomaldegradation of heparan sulfate (HS). It is often unrecognized or misdiagnosed in children as an idiopathic developmental/speech delay, attentiondeficit/hyperactivity disorder (ADHD), and/or autism spectrum disorder. It is characterized by progressive mental deterioration and behavioralproblems with dysmorphic facial features and mild somatic signs. We report on children with ADHD who were repeatedly admitted to the pediatricpsychiatry department for sleep disturbances, hyperactivity, and speech delay; and to the emergency department with accidental corrosive substanceingestion. Children with mental retardation, coarse face, and hypertrichosis were referred to the pediatric gastroenterology department for preliminarydiagnosis of MPS. Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, anddecreased HS sulphamidase activity, leading to the diagnosis of MPS III.

Özet

Mukopolisakaridoz tip III (MPS III), ya da sanfilippo sendromu, otozomal resesif kalıtılan heparan sülfat (HS) enziminin lizozomal indirgenmesinde rol alan dört enzimden birinin eksikliğine bağlıdır. Bu çocuklar yanlışlıkla idyopatik konuşma gecikmesi, dikkat eksikliği hiperaktivite sendromu (DEHS) ve/veya otizm tanısı almaktadır. Progressif mental detoriasyon, davranış problemleri, dismorfik yüz bulguları ve hafif somatik bulgularla karakterizedir. Korozif madde alımı nedeniyle acil çocuk ve çocuk gastroenteroloji bölümlerine başvuran alınan öyküde uyku bozuklukları ve geç konuşma şikayetleri bulunan ve bu nedenle de defalarca çocuk psikiyatrisine başvurdukları saptanan MPS III tanısı alan olgular sunulmuştur. Zeka geriliği, kaba yüzü ve hipertrikozu olan çocuklar, MPS ön tanısı için pediatrik gastroenteroloji bölümüne sevk edildi. Lökositlerdeki lizozomal enzim aktivitesi incelemeleri, toplam GAG, heparin ve HS seviyelerinde artış ve HS sülfamidaz aktivitesinde azalma ortaya çıkararak MPS 3 tanısına yol açtı.

🔖

Cite This Article

URGANCI, N., KALYONCU, D., GÜMÜŞTEKİN, R. (2022). Is Mucopolysaccharidosis a Cause of Sleep and Speech Disorders? Report of Four Cases?. JAREM, Cilt: 10 - Sayı: 2, 204–207. https://ajindex.com/articles/558182

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Neufeld E., Muenzer J. The Mucopolysaccharidoses. The Online Metabolic and Molecular Bases of Inherited Disease. OMMBID McGraw- Hill Medical. 8th ed. McGraw-Hill; New York, NY, USA: 2001
  2. Poswar F.D.O, Vairo F, Burin M, Michelin-Tirelli K, Brusius-Facchin A.C, Kubaski F, Souza C.F.M.D, Baldo G, Giugliani R. Lysosomal diseases: Overview on current diagnosis and treatment. Genet. Mol. Biol. 2019;42:165–177
  3. Valstar MJ, Ruijter GJG, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31: 240-52
  4. Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102: 462-70
  5. Meyer A, Kossow K, Gal A, Mühlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2017; 120: 1255-61
  6. Delgadillo V, O’Callaghan Mdel M, Gort L, Coll MJ, Pineda M. Natural history of Sanfilippo syndrome in Spain. Orphanet J Rare Dis 2013; 8: 189
  7. Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA. Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis 2011; 6: 43
  8. Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008; 93: 104-11
  9. Clarke LA, Winchester B, Giugliani R, Tylki-Szymańska A, Amartino H. Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility. Mol Genet Metab 2012; 106: 395-402
  10. Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type A. J Inherit Metab Dis 2014; 37: 431-7
  11. Cross EM, Hare DJ. Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J Inherit Metab Dis 2013; 36: 189-200
  12. White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50(Suppl 5): 26-33
  13. Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2017; 19: 628-35.